{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:17:46Z","timestamp":1787890666673,"version":"build-2784847793"},"reference-count":27,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"abstract":"<jats:p>An increasing number of patients are being diagnosed with metabolic dysfunction\u2010associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including cardiovascular disease and malignancies. The pathogenesis of MASLD stems from a multifactorial interaction among genetic susceptibility, epigenetic modifications and environmental factors, which collectively impair systemic metabolic homeostasis. Current management relies on a combination of lifestyle modification and pharmacotherapy. Resmetirom is the first drug registrated for the treatment of adults with MASLD and moderate to advances fibrosis. Over the next decade, multiple promising pharmacotherapies with diverse mechanisms of action and routes of administration are expected to become available for the treatment of MASLD. This narrative review provides an overview of the evolving pharmacological therapeutic landscape for MASLD, with a focus on novel therapeutic agents in late\u2010stage clinical development as THR\u2010\u03b2 Agonists, GLP\u20101 Receptor Agonists, Dual GLP\u20101\/ GIP Agonists, Glucagon\/GLP\u20101 Dual Agonists, FGF\u201021 Analogues, Pan\u2010PPAR Agonists and FASN Inhibitors. Based on the differences in mechanisms of actions and specific side effects of these therapies, the characteristics of patients with MASLD should be taken into account in the decision which pharmacologic treatment should be initiated in an individual patient. Also, combining different therapies could be beneficial since this appears to possess complementary mechanisms.<\/jats:p>","DOI":"10.1002\/bcp.70795","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:56:06Z","timestamp":1787889366000},"source":"Crossref","is-referenced-by-count":0,"title":["New therapeutic options for metabolic\u2010associated steatotic liver disease"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6989-5226","authenticated-orcid":false,"given":"Tessa","family":"Straatmijer","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Haaglanden Medical Center  The Hague the Netherlands"},{"name":"Department of Clinical Pharmacy Haaglanden Medical Center  The Hague the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midas","family":"Mulder","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Haaglanden Medical Center  The Hague the Netherlands"},{"name":"Department of Hospital Pharmacy Erasmus MC, University Medical Center Rotterdam  Rotterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.5409\/wjcp.v15.i1.111030"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00951.2024"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(21)00308\u20103"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl\u20102022\u2010327672"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v18.i1.111954"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.4070\/kcj.2025.0212"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v17.i2.113149"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(23)00272\u20108"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502242"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304286"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2036205"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(24)00246\u20102"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401943"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401755"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18331"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70196"},{"key":"e_1_2_8_21_1","unstructured":"Glucagon\u2010like peptide 1\u2010based therapies for the treatment of type 2 diabetes mellitus. Available from:https:\/\/www.uptodate.com\/contents\/glucagon-like-peptide-1-based-therapies-for-the-treatment-of-type-2-diabetes-mellitus#H865633"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.70007"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(25)00067\u20106"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.034"},{"key":"e_1_2_8_25_1","unstructured":"CusiK.Efficacy safety and mechanism of action of lanifibranor (IVA337) in patients with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD).2022.https:\/\/cdn.clinicaltrials.gov\/large-docs\/79\/NCT03459079\/Prot_SAP_000.pdf"},{"key":"e_1_2_8_26_1","unstructured":"A phase I pharmacokinetic study of TVB\u20102640 (denifanstat) in subjects with mild moderate or severe hepatic impairment compared to subjects with normal hepatic function.2023; Available from:https:\/\/www.centerwatch.com\/clinical-trials\/listings\/NCT05835180\/a-phase-i-pharmacokinetic-study-of-tvb-2640-denifanstat-in-subjects-with-mild-moderate-or-severe-hepatic-impairment-compared-to-subjects-with-normal-hepatic-function"},{"key":"e_1_2_8_27_1","unstructured":"A drug\u2010drug interaction study of denifanstat and resmetirom in healthy adult participants. Available from:https:\/\/clinicaltrials.gov\/study\/NCT07216313"},{"key":"e_1_2_8_28_1","unstructured":"Sagimet Biosciences.Announces positive results from the phase 1 PK clinical trial of denifanstat and resmetirom combination.2025; Available from:https:\/\/ir.sagimet.com\/node\/8306\/pdf"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70795","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70795","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:56:08Z","timestamp":1787889368000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":27,"alternative-id":["10.1002\/bcp.70795"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70795","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"bcp.70795"}}